Fi­nance News

BioSpectrum (Asia) - - Bio Content -

Ja­pan based Aska Phar­ma­ceu­ti­cals Co. and Om­ni­care Drugs In­dia Pvt Ltd, a 100 per cent sub­sidiary of the UAE’s largest phar­ma­ceu­ti­cal man­u­fac­turer Neopharma LLC, have es­tab­lished a joint ven­ture (JV) to set up a man­u­fac­tur­ing fa­cil­ity in Visakha­p­at­nam.

The fo­cus of this state-of-theart fa­cil­ity, which will come up by 2020 at the cost of Rs 350 crore, will be to man­u­fac­ture oral solid dosage forms, oral liq­uids and top­i­cal prepa­ra­tions. It will have a peak ca­pac­ity to man­u­fac­ture 3 bil­lion tablets a year.

The fo­cus will be to man­u­fac­ture prod­ucts tar­get­ing chronic ther­a­pies in car­dio­vas­cu­lar dis­eases, cen­tral ner­vous sys­tem and di­a­betes along with other drugs from key ther­a­peu­tic classes tar­get­ing Ja­pan and world mar­ket.

The two com­pa­nies have en­tered into this agree­ment with the pur­pose of man­u­fac­tur­ing and mar­ket­ing of phar­ma­ceu­ti­cals to global mar­ket.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.